From biomarker-driven therapies to antibody-drug conjugates, new treatments are offering more personalised and effective options for triple negative breast cancer (TNBC), an aggressive subtype of breast cancer. These innovations are helping improve survival rates and transforming how TNBC is managed, but they also come with unique challenges that require careful clinical consideration.
Log In or Register as a healthcare professional to read the full article.
